Prevention of type 1 diabetes:: from the view point of β cell damage

被引:95
作者
Kawasaki, E
Abiru, N
Eguchi, K
机构
[1] Nagasaki Univ, Hosp Med & Dent, Dept Metab Diabet & Clin Nutr, Nagasaki 8528501, Japan
[2] Nagasaki Univ, Grad Sch Biomed Sci, Dept Internal Med 1, Nagasaki 8528501, Japan
关键词
type; 1; diabetes; prevention; apoptosis; free radical; cytokine;
D O I
10.1016/j.diabres.2003.09.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The hallmark of immune-mediated type 1 diabetes is T cell-mediated destruction of the insulin-producing beta cells in the islets, which results from an imbalance between disease promoting factors and protective elements. The precise mechanisms of beta cell destruction leading to diabetes remain unclear. There are many molecules, including Fas ligand (FasL) and cytokines, such as IL-1, TNF-alpha and IFN-gamma that cause release of other cytokine-mediators that have potential to damage the beta cells. The beta cell-death appears to ultimately be caused by receptor (Fas/FasL)-mediated mechanisms and/or by secretion of cytotoxic molecules (e.g., granzymes, perforin). FasL-mediated beta cell damage might play a role in promoting insulitis and beta cell destruction in autoimmune diabetes in addition to toxic molecules, such as reactive oxygen species (superoxide, hydroxy radical, nitric oxide) or perform. Furthermore, DNA damage in beta cells leads to poly (ADP-ribose) polymerase-activation which will increase NAD consumption and rapid depletion of NAD compromise ATP production in the cells. Nicotinamide inhibits poly (ADP-ribose) polymerase and reduces nitric oxide accumulation in the NOD pancreas and protect beta cells against radical-induced necrosis. Transgenic mice with beta cell specific overexpression of copper, zinc superoxide dismutase, or thioredoxin are resistant to autoimmune and STZ-induced diabetes. It is apparent that a number of different mechanisms of beta cell destruction are operative in type 1 diabetes. Blockage of multiple pathways, rather than a single pathway, of cell-death may, therefore be necessary to fully protect cells from destruction and thereby prevent type 1 diabetes. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:S27 / S32
页数:6
相关论文
共 44 条
[1]   Cytokine-induced inhibition of insulin release from mouse pancreatic β-cells deficient in inducible nitric oxide synthase [J].
Andersson, AK ;
Flodström, M ;
Sandler, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 281 (02) :396-403
[2]   TNF-ALPHA AND IFN-GAMMA POTENTIATE THE DELETERIOUS EFFECTS OF IL-1-BETA ON MOUSE PANCREATIC-ISLETS MAINLY VIA GENERATION OF NITRIC-OXIDE [J].
CETKOVICCVRLJE, M ;
EIZIRIK, DL .
CYTOKINE, 1994, 6 (04) :399-406
[3]   The role of Fas in autoimmune diabetes [J].
Chervonsky, AV ;
Wang, Y ;
Wong, FS ;
Visintin, I ;
Flavell, RA ;
Janeway, CA ;
Matis, LA .
CELL, 1997, 89 (01) :17-24
[4]   DOES NITRIC-OXIDE MEDIATE AUTOIMMUNE DESTRUCTION OF BETA-CELLS - POSSIBLE THERAPEUTIC INTERVENTIONS IN IDDM [J].
CORBETT, JA ;
MCDANIEL, ML .
DIABETES, 1992, 41 (08) :897-903
[5]   cFLIP protein prevents tumor necrosis factor-α-mediated induction of caspase-8-dependent apoptosis in insulin-secreting βTc-Tet cells [J].
Cottet, S ;
Dupraz, P ;
Hamburger, F ;
Dolci, W ;
Jaquet, M ;
Thorens, B .
DIABETES, 2002, 51 (06) :1805-1814
[6]   PREVENTION OF DIABETES IN NOD MICE TREATED WITH ANTIBODY TO MURINE IFN-GAMMA [J].
DEBRAYSACHS, M ;
CARNAUD, C ;
BOITARD, C ;
COHEN, H ;
GRESSER, I ;
BEDOSSA, P ;
BACH, JF .
JOURNAL OF AUTOIMMUNITY, 1991, 4 (02) :237-248
[7]   Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes [J].
Flodström, M ;
Tyrberg, B ;
Eizirik, DL ;
Sandler, S .
DIABETES, 1999, 48 (04) :706-713
[8]   Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice [J].
Fujihira, K ;
Nagata, M ;
Moriyama, H ;
Yasuda, H ;
Arisawa, K ;
Nakayama, M ;
Maeda, S ;
Kasuga, M ;
Okumura, K ;
Yagita, H ;
Yokono, K .
DIABETES, 2000, 49 (12) :1998-2006
[9]   Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT) [J].
Gale, EAM .
DIABETOLOGIA, 2003, 46 (03) :339-346
[10]  
Gallichan WS, 1999, J IMMUNOL, V163, P1696